- In March 2024, Eli Lilly and Company announced the successful completion of a Phase II clinical trial for a novel targeted therapy aimed at improving survival rates in patients with ameloblastic carcinoma. The therapy showed promising tumor reduction with minimal side effects, highlighting a breakthrough in treatment options.
- In January 2024, Pfizer Inc. disclosed positive interim results from their ongoing study evaluating the efficacy of a BRAF inhibitor in ameloblastic carcinoma patients harboring the BRAF V600E mutation. Early data indicated significant tumor shrinkage and manageable safety profiles.
- In November 2023, AstraZeneca initiated a multi-center Phase I/II clinical trial exploring a new immunotherapy agent targeting PD-1/PD-L1 pathways in ameloblastic carcinoma. This trial aims to enhance the immune response and improve patient outcomes in advanced-stage cases.
